Assignee
SUMITOMO PHARMA SWITZERLAND GMBH
CH·6 granted patents·3 pending applications·13 citations·filing 2021–2024
Top patents by PatentIndex Score
9 records- 0195US12144809B1Treatment of prostate cancerSUMITOMO PHARMA SWITZERLAND GMBH·Filed 2024·Granted Nov 19, 2024·3 cites·29 claims
- 0295US12097198B2Treatment of prostate cancerSUMITOMO PHARMA SWITZERLAND GMBH·Filed 2022·Granted Sep 24, 2024·4 cites·20 claims
- 0393US12336990B2Treatment of prostate cancerSUMITOMO PHARMA SWITZERLAND GMBH·Filed 2024·Granted Jun 24, 2025·1 cites·30 claims
- 0492US11957684B2Treatment of heavy menstrual bleeding associated with uterine fibroidsSUMITOMO PHARMA SWITZERLAND GMBH·Filed 2022·Granted Apr 16, 2024·2 cites·22 claims
- 0591US11793812B2Methods of treating endometriosisSUMITOMO PHARMA SWITZERLAND GMBH·Filed 2021·Granted Oct 24, 2023·2 cites·4 claims
- 0689US2025082632A1Treatment of prostate cancerSUMITOMO PHARMA SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 0787US12338249B2Crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyureaSUMITOMO PHARMA SWITZERLAND GMBH·Filed 2022·Granted Jun 24, 2025·1 cites·20 claims
- 0880US2024165118A1Treatment of Heavy Menstrual Bleeding Associated with Uterine FibroidsSUMITOMO PHARMA SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 0965US2025066382A1Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyureaSUMITOMO PHARMA SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SUMITOMO PHARMA SWITZERLAND GMBH files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →